Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives
- 02.10.2022
- Topic Paper
Erschienen in:
- Verfasst von
-
Igor Tsaur
Igor Tsaur
-
Igor Tsaur, Roman A. Blaheta and Robert Dotzauer contributed as first authors.
- Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany
-
-
Roman A. Blaheta
Roman A. Blaheta
-
Igor Tsaur, Roman A. Blaheta and Robert Dotzauer contributed as first authors.
- Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany
-
-
Robert Dotzauer
Robert Dotzauer
-
Igor Tsaur, Roman A. Blaheta and Robert Dotzauer contributed as first authors.
- Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany
-
-
Maximilian P. Brandt
Maximilian P. Brandt
- Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany
-
Giorgio Gandaglia
Giorgio Gandaglia
- Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
-
Ioanel Sinescu
Ioanel Sinescu
- Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, 00238, Bucharest, Romania
- University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
-
Cristian Mirvald
Cristian Mirvald
-
Igor Tsaur, Roman A. Blaheta and Robert Dotzauer contributed as first authors.
- Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, 00238, Bucharest, Romania
- University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
-
-
Jonathan Olivier
Jonathan Olivier
-
Igor Tsaur, Roman A. Blaheta and Robert Dotzauer contributed as first authors.
- Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France
- Université de Lille Faculté de Médecine Henri Warembourg, Lille, France
- CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Univ. Lille, 59000, Lille, France
-
-
Cristian Surcel
Korrespondierender Autor Cristian Surcel
-
Igor Tsaur, Roman A. Blaheta and Robert Dotzauer contributed as first authors.
- Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, 00238, Bucharest, Romania
- University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
-
- the EAU-YAU Prostate Cancer Working Party
- Erschienen in
- World Journal of Urology | Ausgabe 8/2023
Abstract
Purpose
Focal therapy (FT) is gaining increasing acceptance in the management of localized prostate cancer particularly due to its favorable safety. Preliminary evidence suggests advantageous utilization of local treatment in the field of oligometastatic prostate cancer (OMPC). Since data on the utilization of FT in OMPC are scarce, we sought to summarize available evidence.
Methods
For this narrative comprehensive review, we employed PubMed®, Web of Science™, Embase®, Scopus®, and clinicaltrial.gov databases and Google web search engine to seek peer-reviewed articles, published abstracts from international congresses, and ongoing trials in the English language using the terms “prostate cancer”, “oligometastatic”, “hormone-sensitive”, “focal therapy”, “focal treatment”, “cryotherapy”, “ablation”, “cancer” as well as “metastasis-directed therapy. We focused on relevant publications on FT utilized in OMPC targeting the primary or metastatic sites as well as completed and ongoing clinical trials.
Results
Growing evidence points to distinct differences in the biologic behavior and molecular signaling processes of OMPC as compared to polymetastatic disease (PMPC). No established biomarkers are available to accurately identify OMPC yet, while several candidates are currently under investigation. The evolution of molecular imaging is set to aid in selecting patients benefitting most from local management. Differences between OMPC and PMPC should be considered when designing the optimal therapeutic strategy. While efficacy data for FT in comparison to standard care in OMPC are scarce, longer progression-free survival and time to castration resistance have been demonstrated for bone metastatic prostate cancer with the primary tumor treated by cryosurgery followed by androgen deprivation therapy (ADT) compared to ADT alone.
Conclusion
Ongoing research efforts are eagerly awaited to better characterize OMPC and establish customized strategies for patients with this condition.
Anzeige
- Titel
- Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives
- Verfasst von
-
Igor Tsaur
Roman A. Blaheta
Robert Dotzauer
Maximilian P. Brandt
Giorgio Gandaglia
Ioanel Sinescu
Cristian Mirvald
Jonathan Olivier
Cristian Surcel
the EAU-YAU Prostate Cancer Working Party
- Publikationsdatum
- 02.10.2022
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
World Journal of Urology / Ausgabe 8/2023
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726 - DOI
- https://doi.org/10.1007/s00345-022-04162-5
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
